ITOS

iTeos Therapeutics, Inc. [ITOS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ITOS Stock Summary

Top 10 Correlated ETFs

ITOS

Top 10 Correlated Stocks

ITOS

In the News

ITOS Financial details

Company Rating
-
Market Cap
420.08M
Income
-112.64M
Revenue
12.6M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
157
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-6.58
Forward P/E
-
PEG
0.3
P/S
6.1
P/B
0.68
P/C
-
P/FCF
-3.41
Quick Ratio
21.45
Current Ratio
21.94
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.15
EPS next Y
-
EPS next Q
-
EPS this Y
-215.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-5.56%
-
-
-
-
SMA20
-14.29%
SMA50
-25%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-9%
ROE
-10%
ROC
-0.14%
Gross Margin
100%
Oper. Margin
-141%
Profit Margin
-93%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.2-18.24
52W High
-68.39%
52W Low
-28.88%
RSI
27
Rel Volume
0.72
Avg Volume
280.8K
Volume
202.92K
Perf Week
-12.73%
Perf Month
-23.93%
Perf Quarter
-37.88%
Perf Half Y
-45.81%
-
-
-
-
Beta
1.194
-
-
Volatility
0.32%, 0.44%
Prev Close
-4.69%
Price
5.69
Change
-7.93%

Something similar

Top by Market Cap
AMZN
BRK-A
MSF.DE
CMC.DE
M&M.NS
Top Correlated ETFs
IDNA
IBBQ
BIB
BBC
HDRO
Top Correlated Stocks
SANA
ALOT
RLAY
INO
GLSI
Similar Market Cap
CEVA
IDLV
YRD
5G5.DE
0406.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 280.8K
  • Market Capitalization 420.08M
  • Employee 157
  • CEO Dr. Michel Detheux Ph.D.
  • Headquarters Cambridge,MA,US
  • IPO Date 2020-07-24
  • Website https://www.iteostherapeutics.com

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.